Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

18.09.2014: UCB waives repayment of shareholder loan to WILEX - WILEX AG today announced that the shareholder UCB Pharma S.A. waived its claim for repayment of the shareholder loan to WILEX in the amount of 2.5 million Euro as well as interest of 100,000 Euro accrued in 2014....More


Seite gelesen: 184351 | Heute: 85